Every 10-Q that NEWHYDROGEN INC (NEWH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NEWH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEWH filings page.
NewHydrogen, Inc. is developing ThermoLoop™ thermochemical green hydrogen technology and remained pre-revenue in Q2 2026. For the quarter it recorded a net loss of $917,822, and a six‑month net loss of $1,740,818, driven by higher R&D of $674,387 and G&A of $861,116.
Cash declined to $739,528 at June 30, 2026, with working capital of $788,355 and a shareholders’ deficit of $2,643,279. The accumulated deficit reached $182,530,308, and management states that these conditions raise substantial doubt about continuing as a going concern within one year. The company raised $763,035 by issuing 46.4 million shares under a $3,000,000 equity purchase agreement and later issued a further 5.3 million shares in July. It continues funding a thermochemical water‑splitting research program at UC Santa Barbara, amended to total $1,690,038, while management believes existing cash will cover about four months of planned spending and that additional equity or debt financing will be required in 2026.
NewHydrogen, Inc. reported no revenue and a net loss of $822,996 for the three months ended March 31, 2026, wider than the $476,094 loss a year earlier. Operating expenses rose to $822,701, driven mainly by higher general and administrative and research and development spending.
Cash declined to $714,341 from $1,436,928 at December 31, 2025, and working capital fell to $751,663. The company has an accumulated deficit of $181,612,486 and discloses “substantial doubt” about its ability to continue as a going concern, expecting current working capital to cover roughly three months of operating expenses.
NewHydrogen relies heavily on external funding, including an equity financing agreement with GHS for up to $3,000,000, under which 63,431,529 shares had been issued as of March 31, 2026. Potential dilution is significant, with 565,000,000 stock options and 228,958,334 warrants outstanding, while common shares outstanding reached 789,554,228 as of May 15, 2026.
NewHydrogen, Inc. reported Q3 2025 results with no revenue and a wider year‑to‑date loss. Net loss was $1,581,894 for the nine months ended September 30, 2025, including a Q3 loss of $482,096. Operating expenses totaled $1,582,324 year to date, driven by higher general and administrative, research and development, and selling and marketing spending.
Cash was $1,306,271 at September 30, 2025, down from $2,104,521 at year‑end, after $1,413,695 used in operations. The company raised $615,445 via its equity financing agreement with GHS, issuing 25,245,680 shares and 803,536 shares for a $30,000 commitment fee. Shareholders’ equity (deficit) was $(2,111,010), and accumulated deficit reached $179,524,441. Working capital was $1,318,162. Management references going‑concern uncertainty but believes current resources support about nine months of operations. As of November 10, 2025, common shares outstanding were 759,218,392. Subsequent to quarter‑end, additional shares were issued to GHS under the financing agreement.